Advertisement

Pathology & Oncology Research

, Volume 25, Issue 1, pp 341–348 | Cite as

Pim-2 Cooperates with Downstream Factor XIAP to Inhibit Apoptosis and Intensify Malignant Grade in Prostate Cancer

  • Ke RenEmail author
  • Xin Gou
  • Mingzhao Xiao
  • Weiyang He
  • Jian Kang
Original Article
  • 101 Downloads

Abstract

To find the exact downstream effector of Pim-2 pathway in prostate cancer cells, and to determine the means by which it affects prostate cancer. XIAP, Pim-2 and p-eIF4B expressions were detected in PCA and BPH tissues. Then the Pim-2 and XIAP expressions were manipulated using transfection or RNAi in prostatic cells. Finally, Pim-2/eIF4B/XIAP levels were examined in PCA tissues with different clinicopathologic features. XIAP was significantly higher in PCA than in BPH tissues. When Pim-2 was transfected into noncancerous prostate epithelial cells RWPE-1, Pim-2, p-eIF4B and XIAP were all significantly increased and the apoptosis rate was significantly decreased. When XIAP was transfected into RWPE-1 cells, XIAP was significantly increased with no impact on Pim-2, p-eIF4B and the apoptosis rate. When Pim-2 SiRNA was transfected into prostate cancer cells PC-3, Pim-2, p-eIF4B and XIAP were significantly decreased and the apoptosis rate was significantly increased. When XIAP SiRNA was transfected into PC-3 cells, XIAP was significantly decreased with no impact on Pim-2, p-eIF4B and apoptosis rate. Pim-2, p-eIF4B and XIAP were all significantly higher in PCA tissues with GS ≥8 than those with GS ≤7. XIAP is the downstream factor of Pim-2 pathway in prostate cancer cells. Pim-2 and XIAP cooperate in inhibiting the apoptosis of prostate cancer cells. The activation of Pim-2 pathway may predict higher GS in prostate cancer.

Keywords

Pim-2 XIAP Apoptosis Malignant grade 

Notes

Funding

National Natural Science Foundation of China (81101945).

Chongqing Municipal Public Health Bureau (2011–2-038).

Chongqing Science and Technology Commission (cstc2016jcjA0099).

Supplementary material

12253_2017_353_MOESM1_ESM.doc (31 kb)
ESM 1 (DOC 31 kb)
12253_2017_353_MOESM2_ESM.doc (15 kb)
ESM 2 (DOC 15 kb)
12253_2017_353_MOESM3_ESM.doc (30 kb)
ESM 3 (DOC 30 kb)
12253_2017_353_MOESM4_ESM.doc (1.4 mb)
ESM 4 (DOC 1463 kb)
12253_2017_353_MOESM5_ESM.doc (32 kb)
ESM 5 (DOC 32 kb)

References

  1. 1.
    White E (2003) The Pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes Dev 17(15):1813–1816.  https://doi.org/10.1101/gad.1123103 CrossRefGoogle Scholar
  2. 2.
    Ren K, Gou X, Xiao M, Wang M, Liu C, Tang Z, He W (2013) The over-expression of Pim-2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B. Prostate 73(13):1462–1469.  https://doi.org/10.1002/pros.22693 CrossRefGoogle Scholar
  3. 3.
    Yang J, Wang J, Chen K, Guo G, Xi R, Rothman PB, Whitten D, Zhang L, Huang S, Chen JL (2013) eIF4B phosphorylation by pim kinases plays a critical role in cellular transformation by Abl oncogenes. Cancer Res 73(15):4898–4908.  https://doi.org/10.1158/0008-5472.CAN-12-4277 CrossRefGoogle Scholar
  4. 4.
    Shahbazian D, Parsyan A, Petroulakis E, Topisirovic I, Martineau Y, Gibbs BF, Svitkin Y, Sonenberg N (2010) Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol Cell Biol 30(6):1478–1485.  https://doi.org/10.1128/MCB.01218-09 CrossRefGoogle Scholar
  5. 5.
    Swanson GP, Basler JW (2010) Prognostic factors for failure after prostatectomy. J Cancer 2:1–19 PMID: 21197260CrossRefGoogle Scholar
  6. 6.
    Mand G-H, Meier P (2010) IAPs: from caspase inhibitors to modulators of nf-kappab, inflammation and cancer. Nat Rev Cancer 10(8):561–574.  https://doi.org/10.1038/nrc2889 CrossRefGoogle Scholar
  7. 7.
    Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V (2011) Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 118(3):693–702.  https://doi.org/10.1182/blood-2010-12-323022 CrossRefGoogle Scholar
  8. 8.
    Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V (2009) Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 114(19):4150–4157.  https://doi.org/10.1182/blood-2009-03-212852 CrossRefGoogle Scholar
  9. 9.
    Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM, Thompson TC, Rowley D (2004) Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 64(17):6082–6090.  https://doi.org/10.1158/0008-5472.CAN-04-0838 CrossRefGoogle Scholar
  10. 10.
    Kapelko-Słowik K, Urbaniak-Kujda D, Wołowiec D, Jaźwiec B, Dybko J, Jakubaszko J, Słowik M, Kuliczkowski K (2013) Expression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival. Postepy Hig Med Dosw (Online) 67:553–559 PMID: 23752607CrossRefGoogle Scholar
  11. 11.
    Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K, Miki H, Nakamura S, Harada T, Fujii S, Kagawa K, Endo I, Yata K, Sakai A, Ozaki S, Matsumoto T, Abe M (2011) The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 25(7):1182–1188.  https://doi.org/10.1038/leu.2011.60 CrossRefGoogle Scholar
  12. 12.
    Ren K, Zhang W, Shi Y, Gong J (2010) Pim-2 activates API-5 to inhibit the apoptosis of hepatocellular carcinoma cells through NF-kappaB pathway. Pathol Oncol Res 16(2):229–237.  https://doi.org/10.1007/s12253-009-9215-4 CrossRefGoogle Scholar
  13. 13.
    Park YH, Seo SY, Lee E, JH K, Kim HH, Kwak C (2013) Simvastatin induces apoptosis in castrate resistant prostate cancer cells by deregulating nuclear factor-κB pathway. J Urol 189(4):1547–1552.  https://doi.org/10.1016/j.juro.2012.10.030 CrossRefGoogle Scholar
  14. 14.
    Kim HR, Park CG, Jung JY (2014) Acacetin (5,7-dihydroxy-4′-methoxyflavone) exhibits in vitro and in vivo anticancer activity through the suppression of NF-κB/Akt signaling in prostate cancer cells. Int J Mol Med 33(2):317–324.  https://doi.org/10.3892/ijmm.2013.1571 CrossRefGoogle Scholar
  15. 15.
    Zhang P, Chen L, Song Y, Li X, Sun Y, Xiao Y, Xing Y (2016) Tetraiodothyroacetic acid and transthyretin silencing inhibit pro-metastatic effect of L-thyroxin in anoikis-resistant prostate cancer cells through regulation of MAPK/ERK pathway. Exp Cell Res 347(2):350–359.  https://doi.org/10.1016/j.yexcr.2016.08.019 CrossRefGoogle Scholar
  16. 16.
    Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC, Glinsky GV (2005) Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res 65:2378–2386.  https://doi.org/10.1158/0008-5472.CAN-04-2649 CrossRefGoogle Scholar
  17. 17.
    Nomura T, Yamasaki M, Nomura Y, Mimata H (2005) Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep 14:993–997 PMID: 16142363Google Scholar
  18. 18.
    Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M, Reed JC (2000) Expressionand prognostic signicance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6:1796–1803 PMID: 10815900Google Scholar
  19. 19.
    Rodríguez-Berriguete G, Torrealba N, Ortega MA, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Guil-Cid M, Fraile B, Royuela M (2015) Prognostic value of inhibitors of apoptosis proteins (IAPs) and caspases in prostate cancer: caspase-3 forms and XIAP predict biochemical progression after radical prostatectomy. BMC Cancer 15:809.  https://doi.org/10.1186/s12885-015-1839-z CrossRefGoogle Scholar
  20. 20.
    Seligson DB, Hongo F, Huerta-Yepez S, Mizutani Y, Miki T, Yu H, Horvath S, Chia D, Goodglick L, Bonavida B (2007) Expression of x-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res 13(20):6056–6063.  https://doi.org/10.1158/1078-0432.CCR-07-0960 CrossRefGoogle Scholar
  21. 21.
    Hwang C, Oetjen KA, Kosoff D, Wojno KJ, Albertelli MA, Dunn RL, Robins DM, Cooney KA, Duckett CS (2008) X-linked inhibitor of apoptosis deficiency in the tramp mouse prostate cancer model. Cell Death Differ 15(5):831–840.  https://doi.org/10.1038/cdd.2008.15 CrossRefGoogle Scholar
  22. 22.
    Ferreira CG, van der Valk P, Span SW, Ludwig I, Smit EF, Kruyt FA, Pinedo HM, van Tinteren H, Giaccone G (2001) Expression of x-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res 7(8):2468–2474 PMID: 11489828Google Scholar
  23. 23.
    Aggarwal BB, Ichikawa H (2005) Molecular targets and anticancer potential of indole-3 carbinol and its derivatives. Cell Cycle 4(9):1201–1215.  https://doi.org/10.4161/cc.4.9.1993 CrossRefGoogle Scholar
  24. 24.
    Kashkar H (2010) X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. Clin Cancer Res 16(18):4496–4502.  https://doi.org/10.1158/1078-0432.CCR-10-1664 CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2017

Authors and Affiliations

  1. 1.Department of UrologyThe First Affiliated Hospital of Chongqing Medical UniversityChongqingPeople’s Republic of China

Personalised recommendations